Chenchen Yi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chenchen Yi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Maofeng Wang
Department of Biomedical Sciences Laboratory, Affiliated Dongyang Hospital, Wenzhou Medical University, Dongyang, Zhejiang, China
2 shared publications Fulong Zheng
Zhejiang Provincial Key Laboratory of Medical Genetics, College of Laboratory Medicine and Life sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China
1 shared publication- Hezhi Fang
Department of Clinical Laboratory, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication Huihui Jiang
Zhejiang Provincial Key Laboratory of Medical Genetics, College of Laboratory Medicine and Life sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China
1 shared publicationJianling Qiang
Department of Biomedical Sciences Laboratory, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China
1 shared publication- Jianling Qiang
Department of Biomedical Sciences Laboratory , Affiliated Dongyang Hospital of Wenzhou Medical University , Dongyang , Zhejiang , China
1 shared publication
Latest Publications
- Open Access
- 20 January 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (3) , 101513
Multiomics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer
- 20 January 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (3) , 101513
Open AccessMultiomics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer
- Open Access
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 21 (1)
Global epidemiology of thyroid cancer: trends in incidence, mortality, and DALYs from 1990 to 2021
Objectives: This study provides the first comprehensive assessment of the global thyroid cancer burden from 1990 to 2021, focusing on incidence, mortality, and DALYs trends across 204 countries. Methods: Using Global Burden of Disease (GBD) 2021 data, age-standardized rates (ASRs) and estimated annual percentage changes (EAPCs) were calculated. Associations with the Socio-demographic Index (SDI) were analyzed via linear regression. Results: Globally, the age-standardized incidence rate increased from 2.06 to 2.91 per 100,000 (EAPC=1.25), with women accounting for 67 % of cases. Mortality showed a modest decline (EAPC=−0.23), but DALYs remained high (14.57 million in 2021). High-SDI regions, such as North America, accounted for 72 % of cases, reflecting intensive screening, whereas low-SDI regions, particularly Sub-Saharan Africa, contributed 68 % of deaths due to delayed diagnosis. High BMI contributed 1.68 % of DALYs, peaking at 4.26 % in Andean Latin America. Incidence varied significantly across countries, from 7.13 per 100,000 in Saudi Arabia (linked to iodine excess) to 0.014 per 100,000 in Tajikistan (iodine deficiency). Mortality was highest among elderly males, reaching 12.57 per 100,000 in those aged ≥90 years. Conclusions: The rising global burden of thyroid cancer highlights pronounced gender and regional disparities. High-SDI regions should prioritize risk-stratified strategies to reduce overdiagnosis, while low-SDI regions require improved access to healthcare. Targeted efforts in early detection and metabolic risk reduction are critical to mitigate disease burden.
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 21 (1)
Open AccessGlobal epidemiology of thyroid cancer: trends in incidence, mortality, and DALYs from 1990 to 2021
Objectives: This study provides the first comprehensive assessment of the global thyroid cancer burden from 1990 to 2021, focusing on incidence, mortality, and DALYs trends across 204 countries. Methods: Using Global Burden of Disease (GBD) 2021 data, age-standardized rates (ASRs) and estimated annual percentage changes (EAPCs) were calculated. Associations with the Socio-demographic Index (SDI) were analyzed via linear regression. Results: Globally, the age-standardized incidence rate increased from 2.06 to 2.91 per 100,000 (EAPC=1.25), with women accounting for 67 % of cases. Mortality showed a modest decline (EAPC=−0.23), but DALYs remained high (14.57 million in 2021). High-SDI regions, such as North America, accounted for 72 % of cases, reflecting intensive screening, whereas low-SDI regions, particularly Sub-Saharan Africa, contributed 68 % of deaths due to delayed diagnosis. High BMI contributed 1.68 % of DALYs, peaking at 4.26 % in Andean Latin America. Incidence varied significantly across countries, from 7.13 per 100,000 in Saudi Arabia (linked to iodine excess) to 0.014 per 100,000 in Tajikistan (iodine deficiency). Mortality was highest among elderly males, reaching 12.57 per 100,000 in those aged ≥90 years. Conclusions: The rising global burden of thyroid cancer highlights pronounced gender and regional disparities. High-SDI regions should prioritize risk-stratified strategies to reduce overdiagnosis, while low-SDI regions require improved access to healthcare. Targeted efforts in early detection and metabolic risk reduction are critical to mitigate disease burden.